20 March 2020

ASX ANNOUNCEMENT

Baylor Scott & White Expands SOZO Use with New iOS Software

Brisbane, Australia – ImpediMed Limited (ASX.IP), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced an expansion of its partnership with Baylor Scott & White Institute for Rehabilitation (BS&W Rehab) following the upcoming release of its new iOS compatible SOZOapp. Through the partnership, BS&W Rehab will use ImpediMed’s SOZO® Digital Health Platform to implement the Lymphoedema Prevention Program for cancer patients.

Baylor Scott & White Institute for Rehabilitation offers a network of inpatient and outpatient facilities to serve patients across the state of Texas. The network includes four stand-alone rehabilitation hospitals, two rehabilitation units, more than 100 outpatient therapy centers and a full-service home health division.

In this expansion, Baylor Scott & White Institute for Rehabilitation have added 20 SOZO® units to their Lymphoedema Prevention Program, giving them 25 total units under their program.

“At BS&W Rehab, we drive a high standard for outcomes and patient satisfaction,” said PJ Gillard, PT, Vice President of Outpatient Therapy, Baylor Scott and White Institute for Rehabilitation. “The Lymphoedema Prevention Program is a natural fit for our cancer survivorship program. Lymphoedema has a clear impact on the quality of life of our cancer patients and alleviating suffering from lymphoedema through prevention is an inspiring goal.”

“We are proud to work with providers like BS&W Rehab who strive to offer the highest level of care for cancer patients and survivors,” said Richard Carreon, Managing Director and CEO of ImpediMed. “As we continue to iterate and improve SOZO®, the launch of our iOS compatible software will help grow partnerships like this and positively impact the lives of more patients.”

With the launch of iOS compatible SOZOapp, ImpediMed now offers the SOZO® system on both Android and iOS platforms. SOZO® system is HIPAA compliant and developed with the highest level of security in mind.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment, costing the U.S. healthcare system approximately $7 billion every year. The aim of the Lymphoedema Prevention Program (LPP) is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition.

The LPP utilises ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO® device with BIS and their proprietary L-Dex® technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year. Learn more at www.preventlymphoedema.com.
Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact: Mike Bassett, ImpediMed
T: +61 407 431 432
E: mbassett@impedimed.com

Media Contact: Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally. For more information, visit www.impedimed.com.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.